HOWL - NASDAQ
Werewolf Therapeutics, Inc.
$1.04
-3.7%Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotWerewolf Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Strong liquidity. The company has adequate resources to meet short-term liabilities.
Debt-to-Equity Ratio
Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Werewolf Therapeutics, Inc. Balance Sheet
HOWL • NASDAQ
| Werewolf Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
58M | 111M | 134.3M | 129.3M | 157.5M | 92.6M | 17.9M | |
58M | 111M | 134.3M | 129.3M | 157.5M | 92.6M | 17.9M | |
0.0 | 0.0 | 1.4M | 6.9M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 1.4M | 6.9M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 3.4M | 344K | 167K | |
635K | 2.1M | 2.7M | 4M | 100K | 0.0 | 0.0 | |
58.6M | 113.1M | 138.4M | 140.2M | 161.1M | 92.9M | 18.1M | |
NON-CURRENT ASSETS | |||||||
9.9M | 12.3M | 14.8M | 17.5M | 16.3M | 3.1M | 3.4M | |
901K | 1.2M | 21M | 1.2M | 0.0 | 0.0 | 208K | |
5K | 320K | 594K | 1.4M | 1.9M | 362K | 0.0 | |
10.8M | 13.9M | 36.5M | 20M | 18.2M | 3.5M | 3.6M | |
69.4M | 126.9M | 174.8M | 160.2M | 179.3M | 96.4M | 21.7M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
754K | 3M | 1.3M | 1.2M | 2M | 1M | 633K | |
754K | 3M | 1.3M | 1.2M | 2M | 1M | 633K | |
0.0 | 0.0 | 5.2M | 3.1M | 8.6M | 3.5M | 543K | |
1.8M | 0.0 | 6.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
0.0 | 1.6M | 1.6M | 2.1M | 1.1M | 677K | 595K | |
0.0 | 0.0 | 907K | 6.5M | 0.0 | 0.0 | 0.0 | |
33.6M | 10.6M | 3.6M | 11M | 163K | 94K | 273K | |
36.1M | 15.2M | 19.4M | 24M | 11.9M | 5.3M | 2M | |
NON-CURRENT LIABILITIES | |||||||
0.0 | 26.1M | 32.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
759K | 2.8M | 433K | 1.3M | 0.0 | 31K | 41.4M | |
8.4M | 38.4M | 44.1M | 13.9M | 14.6M | 1.9M | 43.9M | |
7.7M | 11M | 12.6M | 14.7M | 15.7M | 2.5M | 3.1M | |
44.6M | 53.5M | 63.5M | 37.9M | 26.5M | 7.2M | 46M | |
SHAREHOLDERS' EQUITY | |||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 34M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 141.1M | 34.1M | |
5K | 5K | 4K | 3K | 2K | 2K | 2K | |
500.2M | 488M | 455.4M | 429M | 405.7M | 0.0 | 102K | |
-475.4M | -414.6M | -344.1M | -306.7M | -252.9M | -51.9M | -24.4M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -34.1M | |
24.8M | 73.4M | 111.4M | 122.3M | 152.8M | 89.2M | -24.3M | |
24.8M | 73.4M | 111.4M | 122.3M | 152.8M | 89.2M | -24.3M | |
SUMMARY | |||||||
69.4M | 126.9M | 174.8M | 160.2M | 179.3M | 96.4M | 21.7M | |
901K | 1.2M | 21M | 1.2M | 0.0 | 0.0 | 208K | |
9.4M | 37.1M | 51.9M | 14.7M | 15.7M | 2.5M | 3.1M | |
-48.5M | -73.9M | -82.4M | -114.6M | -141.9M | -90M | -14.8M | |
45,725,397 | 45,725,397 | 45,725,397 | 45,725,397 | 45,725,397 | 45,725,397 | 45,725,397 |
SEC Filings
HOWL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-K 10-K 2025 FY FY | March 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 27, 2026 | March 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 24, 2026 | February 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 06, 2026 | February 04, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 18, 2025 | December 18, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 04, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 04, 2025 | November 04, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 06, 2025 | October 02, 2025 | 2025 | |
10-Q 10-Q 2025 Q2 Q2 | August 14, 2025 | June 30, 2025 | 2025 |
Related Guides
Continue your HOWL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.